The August Wellness Index Report, published by Wellness Eternal, focuses on the discipline that determines whether longevity science reaches anyone at all. The science of living longer means little until it reaches real people. Translational longevity is the work of closing that gap, and its leading voices converge this October at the Translational Longevity Summit in Boston, hosted by Boston BioLife and the Healthspan Action Coalition.
Key Takeaways
The August Wellness Index Report finds that the gap between laboratory breakthrough and a patient's bedside is where longevity is actually won.
The report identifies three signals: cell science moving from proof of concept to real clinical delivery, evidence emerging as the bridge from research to practice, and clinical strategy and systems proving essential to scaling care.
Three experts are featured across three vantage points: Dr. Camillo Ricordi (University of Miami), Dr. David Barzilai (Harvard Medical School), and Dr. Suzie Robertson (Matrix Biologics).
The Translational Longevity Summit runs October 7 to 11 at the Harvard Enterprise Research Campus in Boston, hosted by Joseph Krieger of Boston BioLife and Bernard Siegel of the Healthspan Action Coalition.
The Wellness Index Report applies a four-step verification process built on expert nomination, customer and patient feedback, clinical review, and ongoing performance tracking.
The Signals
From bench to bedside: cell science gets real. Decades of research in transplantation and cell therapy are moving from specialized centers into the broader longevity conversation. The emphasis is shifting from proof of concept to real clinical delivery, translating foundational science into treatments that can reach patients and reverse, rather than manage, the drivers of disease and aging.
Evidence as the bridge to practice. As longevity claims multiply, the field increasingly rewards those who can separate what is proven from what is merely promising. Translating frontier science into guidance that clinicians, executives and policymakers can act on has become one of the most valuable skills in medicine.
Strategy and systems that scale care. Even the best therapy fails if the system cannot deliver it safely and consistently. A growing emphasis on clinical strategy, operational rigor and smarter care models is proving essential to ensuring scientific advances reach patients through channels that are safe, compliant and built to scale.
The August Features
Dr. Camillo Ricordi, University of Miami. Ricordi is Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Professor of Microbiology and Immunology at the University of Miami. His work anchors the report's first signal: translational cell therapy moving from the laboratory into clinical reality.
Dr. David Barzilai, Harvard Medical School. A longevity medicine physician and Harvard Medical School lecturer, Barzilai focuses on advancing healthy longevity through evidence-based and precision medicine. He served as medical editor of Harvard Health Publishing's Pathways to Longevity, its first Special Health Report dedicated to the field. A diplomate of the American Board of Lifestyle Medicine, he holds a PhD in health services research and serves as inaugural faculty member and trustee at the Geneva College of Longevity Science. He is known for making complex scientific advances accessible and actionable for clinicians, executives and policymakers.
Dr. Suzie Robertson, Matrix Biologics. A clinical pharmacist, healthcare strategist and business developer with nearly two decades of leadership experience across the healthcare continuum, Robertson is recognized for bridging clinical excellence with innovation, helping organizations improve patient safety, operational performance and care delivery models.
The Summit's Hosts
Joseph Krieger, Boston BioLife. Krieger is President and Founder of Boston BioLife, where he has spent more than 25 years at the forefront of healthcare and life sciences. Driven by a vision to streamline translational medicine, uniting laboratory discovery, clinical practice and community impact, he built Boston BioLife to accelerate the integration of cutting-edge technologies into everyday medical practice through accredited education, training and industry collaboration.
Bernard Siegel, Healthspan Action Coalition. Siegel, JD, is founder of the Healthspan Action Coalition and Executive Director of the Regenerative Medicine Foundation. A Florida attorney, cancer survivor and patient advocate, he helped forge the advocacy movement at the foundation of the stem cell and regenerative medicine ecosystem. He conceptualized and co-chaired twenty World Stem Cell Summits and leads the global Pro-Cures Movement, connecting scientists, advocates and policymakers worldwide.
Commentary
"The future of longevity is translational. The breakthroughs are real, but they only matter when they reach people. That is the work these three share, and the reason the field is converging on Boston this October," said Lindsay O'Neill-O'Keefe, Founder of Wellness Eternal and creator of the Wellness Index Report.
"Discovery is only half the job. Delivery is the rest," O'Neill-O'Keefe added. "The future of longevity is not just discovered. It is delivered."
